References
TUMOR NECROSIS
CD3% for potassium canrenoate vs. placebo between day 1 and day 7; Interleukin-1ß total count [%] for potassium canrenoate vs. placebo between day 1 and day 7; TNF-α total count [%] for potassium canrenoate vs. placebo between day 1 and day 7; Interleukin-6 [pg/mL] for potassium canrenoate vs. placebo between day 1 and day 7; Study flowchart.Baseline characteristics.Legend: BMI—body mass index, CFS—Clinical Frailty Scale, Me—median, SD—standard deviation, Laboratory results on day 1.Legend: Me—median, SD—standard deviation, Laboratory results on day 7.Legend: Me—median, SD—standard deviation, Immunophenotype analysis on day 1.Legend: CD—cluster of differentiation, IL—interleukin, TNF—tumor necrosis factor, Me—median, SD—standard deviation, Immunophenotype on day 7.Legend: CD—cluster of differentiation, IL—interleukin, TNF—tumor necrosis factor, Me—median, SD—standard deviation, Intragroup comparisons on day 1 versus day 7.Legend: CD—cluster of differentiation, IL—interleukin, TNF—tumor necrosis factor, Me—median, SD—standard deviation, 